Table 1

Baseline characteristics

VariableShorter duration of CS
(n=56)
Longer duration of CS
(n=109)
P value
Age at ICPi initiation, years, median (IQR)68 (59–75)69 (61–76)0.51
Male, n (%)36 (64.3)69 (63.3)0.99
Race, n (%)0.84
 White47 (83.9)95 (87.2)
 Black4 (7.1)3 (2.8)
 Other/unknown5 (8.9)11 (10.1)
Comorbidities, n (%)
 Hypertension36 (64.3)73 (67.0)0.74
 Diabetes10 (17.9)22 (20.2)0.84
 CHF3 (5.4)4 (3.7)0.69
 COPD0 (0)17 (15.6)<0.01
 Cirrhosis1 (1.8)0 (0)0.34
 Body mass index, median (IQR)26 (23–30)28 (24–31)0.20
Baseline eGFR,* mL/min per 1.73 m2
 Median (IQR)72 (58–85)72 (60–87)0.54
eGFR categories, n (%)0.61
 ≥9012 (21.4)20 (18.4)
 60–8928 (50.0)62 (56.9)
 45–596 (10.7)15 (13.8)
 <4510 (17.9)12 (11.0)
 Extrarenal irAE,† n (%)26 (46.4)57 (52.3)0.51
Malignancy, n (%)0.54
 Lung11 (19.6)29 (26.6)
 Melanoma17 (30.4)28 (29.4)
 Genitourinary17 (34.7)32 (65.3)
Other
 PPI,‡ n (%)28 (50.0)67 (61.5)0.18
 Combo anti-CTLA-4+anti-PD-1/PD-L115 (26.8)27 (24.8)0.85
 Duration of CS, median (IQR)21 (14–25)46 (36–59)<0.01
  • Data are shown as median (IQR) and n (%). All data are complete.

  • *Baseline eGFR was defined based on the closest SCr prior to ICPi initiation, and was calculated based on Chronic Kidney Disease-Epidemiology Collaboration equation.13

  • †Extrarenal irAEs were assessed prior to (>14 days) or concomitant (within 14 days before or after) with ICPi-AKI diagnosis.

  • ‡PPIs were assessed in the 14 days preceding ICPi-AKI diagnosis.

  • AKI, acute kidney injury ; CHF, congestive heart failure; Combo, combination therapy; COPD, chronic obstructive pulmonary disease; CS, corticosteroids; CTLA-4, cytotoxic T lymphocyte-associated antigen 4; eGFR, estimated glomerular filtration rate; ICPi, immune checkpoint inhibitor; irAE, immune-related adverse event; PD-1, programmed cell death 1; PD-L1, programmed death-ligand 1; PPI, proton pump inhibitor; SCr, serum creatinine.